Reuters logo
BRIEF-Syndax Pharmaceuticals announces expansion ongoing phase 2 collaboration with Merck unit
2017年4月27日 / 上午11点19分 / 5 个月前

BRIEF-Syndax Pharmaceuticals announces expansion ongoing phase 2 collaboration with Merck unit

April 27 (Reuters) - Syndax Pharmaceuticals Inc:

* Syndax Pharmaceuticals announces expansion of encore 601/keynote 142, ongoing phase 2 clinical collaboration with a subsidiary of Merck

* Says the expansion to include a cohort of patients with microsatellite stable colorectal cancer

* Syndax Pharmaceuticals - trial designed to evaluate safety, tolerability and efficacy of Syndax’s entinostat in combination with Keytruda

* Syndax Pharmaceuticals - financial and other terms of initial agreement, as well as amendment covering expanded collaboration, were not disclosed Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below